001026693 001__ 1026693
001026693 005__ 20250204113857.0
001026693 0247_ $$2doi$$a10.1021/acs.molpharmaceut.3c01215
001026693 0247_ $$2ISSN$$a1543-8384
001026693 0247_ $$2ISSN$$a1543-8392
001026693 0247_ $$2datacite_doi$$a10.34734/FZJ-2024-03507
001026693 0247_ $$2pmid$$a38747353
001026693 0247_ $$2WOS$$aWOS:001225916700001
001026693 037__ $$aFZJ-2024-03507
001026693 041__ $$aEnglish
001026693 082__ $$a610
001026693 1001_ $$0P:(DE-Juel1)180812$$aGröner, Benedikt$$b0
001026693 245__ $$aRadiosynthesis and Preclinical Evaluation of m-[18F]FET and [18F]FET-OMe as Novel [18F]FET Analogs for Brain Tumor Imaging
001026693 260__ $$aWashington, DC$$bAmerican Chemical Society$$c2024
001026693 3367_ $$2DRIVER$$aarticle
001026693 3367_ $$2DataCite$$aOutput Types/Journal article
001026693 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1718948189_4300
001026693 3367_ $$2BibTeX$$aARTICLE
001026693 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001026693 3367_ $$00$$2EndNote$$aJournal Article
001026693 500__ $$aThis work was supported, in part, by DeutscheForschungsgemeinschaft (DFG) grants ZL 65/1-1, ZL 65/3-1,and ZL 65/4-1.
001026693 520__ $$aO-([18F]Fluoroethyl)-L-tyrosine ([18F]FET) is activelytransported into the brain and cancer cells by LAT1 andpossibly other amino acid transporters, which enables brain tumorimaging by positron emission tomography (PET). However, tumordelivery of this probe in the presence of competing amino acidsmay be limited by a relatively low affinity for LAT1. The aim of thepresent work was to evaluate the meta-substituted [18F]FET analogm-[18F]FET and the methyl ester [18F]FET-OMe, which weredesigned to improve tumor delivery by altering the physicochemical,pharmacokinetic, and/or transport properties. Both tracerscould be prepared with good radiochemical yields of 41−56%within 66−90 min. Preclinical evaluation with [18F]FET as areference tracer demonstrated reduced in vitro uptake of [18F]FETOMeby U87 glioblastoma cells and no advantage for in vivo tumor imaging. In contrast, m-[18F]FET showed significantly improvedin vitro uptake and accelerated in vivo tumor accumulation in an orthotopic glioblastoma model. As such, our work identifies m-[18F]FET as a promising alternative to [18F]FET for brain tumor imaging that deserves further evaluation with regard to its transportproperties and in vivo biodistribution.
001026693 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001026693 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001026693 7001_ $$0P:(DE-Juel1)180770$$aHoffmann, Chris$$b1$$ufzj
001026693 7001_ $$0P:(DE-Juel1)180330$$aEndepols, Heike$$b2
001026693 7001_ $$0P:(DE-Juel1)176705$$aUrusova, Elizaveta$$b3$$ufzj
001026693 7001_ $$0P:(DE-Juel1)131826$$aBrugger, Melanie$$b4$$ufzj
001026693 7001_ $$0P:(DE-Juel1)175142$$aNeumaier, Felix$$b5
001026693 7001_ $$0P:(DE-HGF)0$$aTimmer, Marco$$b6
001026693 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b7$$eCorresponding author
001026693 7001_ $$0P:(DE-Juel1)176188$$aZlatopolskiy, Boris D.$$b8
001026693 773__ $$0PERI:(DE-600)2132489-X$$a10.1021/acs.molpharmaceut.3c01215$$gp. acs.molpharmaceut.3c01215$$p2795-2812$$tMolecular pharmaceutics$$v21$$x1543-8384$$y2024
001026693 8564_ $$uhttps://juser.fz-juelich.de/record/1026693/files/gr%C3%B6ner-et-al-2024-radiosynthesis-and-preclinical-evaluation-of-m-18f-fet-and-18f-fet-ome-as-novel-18f-fet-analogs-for.pdf$$yOpenAccess
001026693 8564_ $$uhttps://juser.fz-juelich.de/record/1026693/files/gr%C3%B6ner-et-al-2024-radiosynthesis-and-preclinical-evaluation-of-m-18f-fet-and-18f-fet-ome-as-novel-18f-fet-analogs-for.gif?subformat=icon$$xicon$$yOpenAccess
001026693 8564_ $$uhttps://juser.fz-juelich.de/record/1026693/files/gr%C3%B6ner-et-al-2024-radiosynthesis-and-preclinical-evaluation-of-m-18f-fet-and-18f-fet-ome-as-novel-18f-fet-analogs-for.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
001026693 8564_ $$uhttps://juser.fz-juelich.de/record/1026693/files/gr%C3%B6ner-et-al-2024-radiosynthesis-and-preclinical-evaluation-of-m-18f-fet-and-18f-fet-ome-as-novel-18f-fet-analogs-for.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
001026693 8564_ $$uhttps://juser.fz-juelich.de/record/1026693/files/gr%C3%B6ner-et-al-2024-radiosynthesis-and-preclinical-evaluation-of-m-18f-fet-and-18f-fet-ome-as-novel-18f-fet-analogs-for.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
001026693 8767_ $$d2024-06-03$$eHybrid-OA$$jPublish and Read
001026693 909CO $$ooai:juser.fz-juelich.de:1026693$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$popen_access$$popenaire
001026693 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180812$$aForschungszentrum Jülich$$b0$$kFZJ
001026693 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180770$$aForschungszentrum Jülich$$b1$$kFZJ
001026693 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180330$$aForschungszentrum Jülich$$b2$$kFZJ
001026693 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)176705$$aForschungszentrum Jülich$$b3$$kFZJ
001026693 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131826$$aForschungszentrum Jülich$$b4$$kFZJ
001026693 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)175142$$aForschungszentrum Jülich$$b5$$kFZJ
001026693 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b7$$kFZJ
001026693 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001026693 9141_ $$y2024
001026693 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
001026693 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
001026693 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
001026693 915pc $$0PC:(DE-HGF)0122$$2APC$$aHelmholtz: American Chemical Society 01/01/2023
001026693 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
001026693 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-26
001026693 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001026693 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
001026693 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001026693 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL PHARMACEUT : 2022$$d2024-12-20
001026693 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
001026693 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
001026693 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
001026693 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
001026693 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-20
001026693 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
001026693 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-20
001026693 920__ $$lyes
001026693 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
001026693 980__ $$ajournal
001026693 980__ $$aVDB
001026693 980__ $$aUNRESTRICTED
001026693 980__ $$aI:(DE-Juel1)INM-5-20090406
001026693 980__ $$aAPC
001026693 9801_ $$aAPC
001026693 9801_ $$aFullTexts